Alaunos Therapeutics effects 1-for-15 reverse stock split effective Jan 31, 2024

Alaunos Therapeutics, Inc.

Reverse stock split at a ratio of 1-for-15, effective January 31, 2024 at 5:00 p.m. ET.
Every 15 pre-split shares converted into 1 share; par value unchanged at $0.001.
Common stock continues trading on Nasdaq under symbol TCRT; new CUSIP 98973P200.
Split ratio chosen by Board on Jan 12, 2024; stockholder authority granted at June 6, 2023 annual meeting.
Equiniti Trust Company appointed as exchange agent for processing share conversions.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alaunos Therapeutics, Inc.: Filed a Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2024-01-31).

Change: charter amendment
Effective: 2024-01-31

Exact text from the filing

On January 31, 2024, Alaunos Therapeutics, Inc. (the “Company”) filed a Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-15 (the “Reverse Split”).

View on SEC.gov

Browse all governance changes →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193805-24-000111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.